
Journey Medical Corporation: stock overview
Price
$4.33
November 13, 2026Market cap $106M
What Ploutos Investor adds for Journey Medical
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
In short
Journey Medical had revenue of $70M over the last 12 months and a net loss of $5.1M. Revenue grew by 6.8% a year on average over the last 5 years. It pays no dividend.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $106M
- 24.50M shares
- P/E
- –
- Revenue, 12 months
- $70M
- +6.8% a year over 5 years
- Net margin
- -7.3%
- 2025: -18.5%, above 34% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
-11.6% a year over 2 years
Fiscal years in figures
DERM's revenue, profit, cash flow and dividend with each year-end price, from 2020 to 2022, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $105M
- $106M
- Enterprise value
- –
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B 3-year median: 5.2
- 3.3
- FCF yield
- –
- Earnings yield 3-year median: -6.1%
- –
Profitability
- Gross margin
- 65.9%
- Operating margin
- -2.9%
- Net margin 3-year median: -18.5%
- -7.3%
- ROIC
- -2.8%
- ROIC, 5-year average
- -32.9%
- ROE
- -16.7%
Growth
- Revenue, yearly change
- +10.2%
- EPS, yearly change
- –
- FCF, yearly change
- -10,152.9%
- Revenue, average a year
- +6.8%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $22M
- Total debt
- –
- Net cash
- –
- Net debt / EBITDA
- –
- Interest cover
- -0.6x
- Current ratio
- 1.48
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +19.9%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).
Operating margin
-13.2%
Above 38% of the 285 companies in its industry, and 17% of all.
Net margin
-18.5%
Above 34% of the 302 companies in its industry, and 14% of all.
ROE
-35.9%
Above 22% of the 267 companies in its industry, and 9% of all.
ROA
-12.1%
Above 31% of the 313 companies in its industry, and 13% of all.
Revenue growth
10.2%
Above 58% of the 292 companies in its industry, and 63% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- Journey Medical Corp
- CIK
- 1867066
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 24.50M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with DERM
- JNJJohnson & Johnson+0,00%Compare with DERM
- ABBVAbbVie+0,00%Compare with DERM
- UNHUnitedHealth+0,00%Compare with DERM
- MRKMerck & Company+0,00%Compare with DERM
- AMGNAmgen+0,00%Compare with DERM
- TMOThermo Fisher Scientific+0,00%Compare with DERM
- ABTAbbott Laboratories+0,00%Compare with DERM
The full analysis
What do Journey Medical's filings show?
These are Journey Medical's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is DERM's market cap?
Journey Medical Corporation's market cap is $106M, at a price of $4.33 on November 13, 2026 and 24.50M shares.
How much revenue does DERM have?
Journey Medical had revenue of $70M over the last 12 months. Over the last 5 years it changed by +6.8% a year on average.
Does DERM pay a dividend?
No. Journey Medical paid no regular dividend over the last 12 months.
Where do the figures come from?
From Journey Medical Corporation's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.